Global Gastric Inhibitory Polypeptide Receptor Market Research Report 2021

(Bussiness Sales)

(Us - Toll Free)

(Rest Of World)

Home / Categories / Healthcare

Global Gastric Inhibitory Polypeptide Receptor Market Research Report 2021

Global Gastric Inhibitory Polypeptide Receptor...

Report Code

RO1/130/9930

Publish Date

23/Mar/2021

PRICE

Single User Licence

$ 1800/-

This is a single user license, allowing one specific user access to the product. The product is a PDF.

Multi User Licence

$ 2350/-

This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.

Corporate User Licence

$ 2850/-

This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..

Report Type

PDF

REQUEST SAMPLE
ASK FOR DISCOUNT
ANY QUESTION

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
HM-15211
LBT-6030
LY-3298176
NNC-92041706
Others

Segment by Application
Metabolic Disorder
Type 2 Diabetes
Obesity
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Alchemia Limited
AstraZeneca Plc
Carmot Therapeutics, Inc.
Diabetica Limited
Longevity Biotech, Inc
Novo Nordisk A/S
Sanofi
Zealand Pharma A/S